Amarin Corp. PLC (AMRN) Sets New 1-Year High at $3.00
Amarin Corp. PLC (NASDAQ:AMRN)’s share price hit a new 52-week high on Monday . The stock traded as high as $3.00 and last traded at $2.89, with a volume of 8,227,859 shares changing hands. The stock had previously closed at $2.65.
Several equities analysts have recently weighed in on the company. Jefferies Group restated a “buy” rating and issued a $3.50 price objective on shares of Amarin Corp. PLC in a report on Thursday, July 7th. Zacks Investment Research cut Amarin Corp. PLC from a “hold” rating to a “sell” rating in a report on Tuesday, May 17th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Amarin Corp. PLC in a report on Monday, May 9th.
The stock’s 50 day moving average is $2.26 and its 200 day moving average is $1.80. The stock’s market capitalization is $586.52 million.
Amarin Corp. PLC (NASDAQ:AMRN) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.03. The company had revenue of $25.30 million for the quarter, compared to analyst estimates of $26.77 million. During the same quarter last year, the firm posted ($0.16) EPS. The firm’s revenue for the quarter was up 60.4% compared to the same quarter last year. Analysts predict that Amarin Corp. PLC will post ($0.49) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Amarin Corp. PLC stock. OppenheimerFunds Inc. boosted its stake in shares of Amarin Corp. PLC (NASDAQ:AMRN) by 0.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,323,360 shares of the biopharmaceutical company’s stock after buying an additional 27,090 shares during the period. OppenheimerFunds Inc. owned about 2.90% of Amarin Corp. PLC worth $10,061,000 at the end of the most recent reporting period.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.